MIRA
INFORM REPORT
|
Report Date : |
29.06.2007 |
IDENTIFICATION DETAILS
|
Name : |
GENESIS TIBBI URUNLER SANAYI VE PAZARLAMA A.S. |
|
|
|
|
Registered Office : |
Esenboga Yolu 22.Km Akyurt Ankara |
|
|
|
|
Country : |
|
|
|
|
|
Date of Incorporation : |
02.07.2003 |
|
|
|
|
Com. Reg. No.: |
295 |
|
|
|
|
Legal Form : |
Joint Stock Company |
|
|
|
|
Line of Business : |
The firm which was dealing with trade of medical
materials, started to trial manufacture of those medical materials in 2007.
However it has not sold those trial production yet. |
RATING & COMMENTS
|
MIRA’s Rating : |
Ca |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
Status : |
Moderate |
|
|
|
|
Payment Behaviour : |
Usually correct |
|
|
|
|
Litigation : |
Clear |
COMPANY
IDENTIFICATION
|
NAME |
: |
GENESIS TIBBI URUNLER SANAYI VE PAZARLAMA A.S. |
|
ADDRESS |
: |
Head Office/Production Plant: Esenboga
Yolu 22.Km Akyurt Ankara/Turkey |
|
PHONE NUMBER |
: |
90-312-398 02 40 90-312-840 54 50 |
|
FAX NUMBER |
: |
90-312-840 54 55 |
LEGAL STATUS AND
HISTORY
|
TAX OFFICE / NO |
: |
Cubuk/3940322322 |
|
|
|
REGISTRATION NUMBER |
: |
295-Akyurt |
|
|
|
REGISTERED OFFICE |
: |
|
|
|
|
DATE ESTABLISHED |
: |
02.07.2003 (Commercial Registry Gazette
Date/No:08.07.2003/5836) |
|
|
|
LEGAL FORM |
: |
Joint Stock Company |
|
|
|
TYPE OF COMPANY |
: |
Private |
|
|
|
REGISTERED CAPITAL |
: |
YTL 1,000,000 |
|
|
|
PAID-IN CAPITAL |
: |
The paid in capital
is declared to be YTL 569,000. There is no certification for paid in
capital.
|
|
|
|
HISTORY |
: |
|
|
|
|
|
|
Previous Registered Capital |
:YTL 50,000 |
|
|
|
|
Regist. Capital Changed on |
: 2004 (Commercial Registry Gazette
Date/No: 20.07.2004/6096) |
|
|
|
|
Previous Address |
:Turgut Reis Cad 15/1 Mebusevleri-Ankara |
|
|
|
|
Address Changed On |
: 02.12.2004 (Commercial Registry Gazette Date/No:
07.12.2004/6192) |
|
OWNERSHIP /
MANAGEMENT
|
SHAREHOLDERS |
: |
Yusuf Ozturk Bulent Ozturk Asu Oktem Zekeriya Ozgun Nesrin Ozgun |
20 % |
|
SISTER COMPANIES |
: |
Declared to be: None |
|
|
GROUP PARENT COMPANY |
: |
None |
|
|
SUBSIDIARIES |
: |
None |
|
|
BOARD OF DIRECTORS |
: |
Yusuf Ozturk Nihat Armaca Nesrin Ozgun |
Chairman Vice-chairman Member |
|
DIRECTORS |
: |
Yusuf Ozturk |
General Manager |
OPERATIONS
|
BUSINESS ACTIVITIES |
: |
The firm which was dealing with trade of
medical materials, started to trial manufacture of those medical materials in
2007. However it has not sold those trial production yet. The subject has declared that it is the
distributor of the following companies: -Permedica SPA ( -Genesistech ( |
|
|
SECTOR |
: |
Medical |
|
|
TRADEMARK(S) |
: |
“Cyborg” |
|
|
NUMBER OF
EMPLOYEES |
: |
26 |
|
|
NET SALES |
: |
n.a. |
|
|
|
|
In However the company strictly declines to give us an authorization to gather
its financial data. As the firm’s shares are not open to public it is not
obliged to announce its data. |
|
|
IMPORT COUNTRIES |
: |
|
|
|
MERCHANDISE
IMPORTED |
: |
Medical materials |
|
|
EXPORT COUNTRIES |
: |
|
|
|
MERCHANDISE
EXPORTED |
: |
Artificial body parts |
|
|
PREMISES |
: |
Head Office/Production Plant: Esenboga
Yolu 22.Km Akyurt Ankara (15,695 sqm) (rented) |
|
|
FIXED CAPITAL
INVESTMENTS |
: |
Investments are going on |
|
COMMERCIAL MORALITY : Good
FINANCE
|
MAIN DEALING BANKERS |
: |
T.Ziraat Bankasi Cubuk branch in T.Is Bankasi Baskent branch in |
|
PAYMENT BEHAVIOUR |
: |
No complaints have been heard regarding
payments from banks. According
to the official registries since its establishment on 02.07.2003 until
15.04.2007, there are no protested bills and non-paid cheques registered in
the name of “Genesis Tibbi” |
COMMENT ON FINANCIAL
POSITION
|
GENERAL
FINANCIAL POSITION |
|
Undetermined; the firm declines to give us an authorization to gather
its financial data. As the shares of
the firm are not open to public, it is not obliged to announce its data. |
CREDIT OPINION
CREDIT OPINION WITHOUT OBLIGATION : In view of
the lack of detailed financial data, we have no basis to
talk about a business relation without security.
|
|
Incr. in
producers’ price index |
Average YTL/$ |
Average YTL/EUR |
Average YTL/GBP |
|
(2006) |
11.58 % |
1.4309 |
1.7987 |
2.6377 |
|
(1.1.-31.05.2007) |
3.09 % |
1.3821 |
1.8357 |
2.7229 |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest capability
for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Unfavourable & favourable factors carry similar weight in credit
consideration. Capability to overcome financial difficulties seems comparatively
below average/normal. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
NR |
In view of the lack of information, we have no basis upon which to
recommend credit dealings |
No Rating |
|
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a
composite of weighted scores obtained from each of the major sections of this
report. The assessed factors and their relative weights (as indicated through
%) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)